retatrutide triple agonist glp-1 gip glucagon phase 3 2025 First data, a Triumph of Science! retatrutide phase 3 2025 triple

The mean weight loss reached 28.3% at 80 weeks and 30.3% at 104 weeks in the higher-BMI cohort [1]

Reached your goal weight using medication but need help maintaining

Areas to Avoid Avoid injecting into: Areas with scar tissue Areas with bruising or injuries Directly around moles or birthmarks Infected or inflamed skin areas Directly above or below joint areas Peptide nghin cu cht lng dc phm i vi ng dng nghin cu, tinh khit ca peptide l yu t quyt nh cho kt qu ng tin cy

Weigh yourself weekly at the same time, under the same conditions, but do not overreact to short-term fluctuations

1 Most GLP-1 drugs are often administered through an injection pen, but there are some available to take orally

Breining, P